Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Artificial Intelligence Is Future Of Postmarketing Surveillance, US FDA’s Marks Says

Executive Summary

CBER director’s vision for a national safety surveillance system includes use of AI and natural language processing to enable near-real time signal detection from adverse event reports.

You may also be interested in...



US FDA Seeks Funding To Modernize Inspection-Related Technology Systems

Head of agency’s inspectorate stresses need to invest in new IT infrastructure for manufacturing site inspections. New FDA Inspectional Affairs Council leads the charge.

Biden Requests US FDA Budget Surge: Pandemic Preparedness Money Would Increase Funding 36%

President Biden’s budget request would add $1.63bn in mandatory funding to the FDA budget in FY 2023.

US FDA To Explore New Regulatory Pathways For Some Cellular Products

Agency re-evaluating criteria for certain human cells, tissues and cellular and tissue-based products (HCT/Ps) that are not ideally regulated as BLAs; industry suggests a 2014 guidance which created an alternative pathway for cord blood products could serve as potential template.

Topics

UsernamePublicRestriction

Register

PS146156

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel